Tuesday , December 12 2017
Home / Resources / Articles / Once-Daily Levemir® as Effective as Glargine Over 24Hrs For Type 2’s

Once-Daily Levemir® as Effective as Glargine Over 24Hrs For Type 2’s

We often have heard that Levemir has to be high dose to have the same 24 hour effect as Lantus. Now a new head to head study dispels that rumor. It appears that Detimir can be used once-daily and have a comparable blood glucose response to insulin glargine over a 24-hour period in patients with type 2 diabetes.

“Our study reinforces that once-daily Levemir has a similar 24-hour action profile as once-daily glargine,” said Professor Allen B. King, Diabetes Care Center, Salinas, CA, whose research compared 24-hour blood glucose response of Levemir and glargine. 

A retrospective study using recent data from a large US health plan database showed that in addition to providing similar blood glucose response as glargine, Levemir had no significant difference vs. glargine in daily average consumption and diabetes related pharmacy costs.

The head-to-head, randomized, double-blind crossover study compared the blood glucose response of once-daily Levemir to glargine in a single daily dose over a 24-hour period using continual glucose monitoring system (CGMS), showing that Levemir had a comparable blood glucose response to insulin glargine.

Patients with type 2 diabetes using basal insulin without bolus insulin (N=35) were randomized to receive a single daily injection of Levemir or glargine at 8 p.m. for one week in order to achieve steady state levels of insulin in the body.  At the end of the week, subjects were switched to the other insulin.

Both insulins were titrated to achieve blood glucose targets during a pre-specified basal period (12 p.m. to 6 a.m.).  No food was eaten between 6 p.m. to ~7 a.m. in order to obtain accurate basal readings.

Once basal blood glucose targets were achieved, CGMS readings for the last 24-hour period were recorded and mean values were compared between treatments using a single-tailed, paired t-test.

Results show that both insulins work at the same average units and cost.

Presented at the American Diabetes Association 68th Scientific Sessions held in San Francisco, California.